1285513-38-3

Basic information

• Product Name: 2-(benzyloxy)-5-bromo-N-(pyridazin-4-yl)benzamide
• Synonyms: 2-(benzyloxy)-5-bromo-N-(pyridazin-4-yl)benzamide
• CAS NO: 1285513-38-3
• Molecular Weight: 384.232
• Mol File: 1285513-38-3.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 2-(benzyloxy)-5-bromo-N-(pyridazin-4-yl)benzamide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(benzyloxy)-5-bromo-N-(pyridazin-4-yl)benzamide(1285513-38-3)
• EPA Substance Registry System: 2-(benzyloxy)-5-bromo-N-(pyridazin-4-yl)benzamide(1285513-38-3)

Safety Data

• Hazardous Substances Data: 1285513-38-3(Hazardous Substances Data)

Usage

General Description

2-(benzyloxy)-5-bromo-N-(pyridazin-4-yl)benzamide is a compound with the molecular formula C21H16BrN3O2. It is a benzamide derivative with a benzyl ether group and a bromo substituent on the benzene ring. Additionally, it contains a pyridazine-4-yl group attached to the amide nitrogen atom. This chemical compound may have potential pharmaceutical applications due to its structural features, and further research into its properties and potential uses may be warranted.

Upstream product

• 850350-09-3 phenylmethyl 5-bromo-2-[(phenylmethyl)oxy]benzoate 
• 20744-39-2 4-aminopyridazine 
• 62176-31-2 5-bromo-2-[(phenylmethyl)oxy]benzoic acid 
• 89-55-4 5-bromosalicyclic acid 

Downstream Products

• 1285514-64-8 2-[(phenylmethyl)oxy]-N-4-pyridazinyl-5-(4-pyridinyl)benzamide 
• 1285514-61-5 5-(1-methyl-1H-pyrazol-4-yl)-2-[(phenylmethyl)oxy]-N-4-pyridazinylbenzamide 

Relevant articles and documents

5-Substituted-N-pyridazinylbenzamides as potent and selective LRRK2 inhibitors: Improved brain unbound fraction enables efficacy

We describe the discovery and optimization of 5-substituted-N-pyridazinylbenzamide derivatives as potent and selective LRRK2 inhibitors. Extensive SAR studies led to the identification of compounds 18 and 23, which demonstrated good in vitro pharmacokinetic profile and excellent selectivity over 140 other kinases. Both compounds demonstrated high unbound fractions in both blood and brain. Compound 18 proved to be brain penetrant, and the high unbound fraction of compound 18 in brain enabled its in vivo efficacy in CNS, wherein a significant inhibition of LRRK2 Ser935 phosphorylation was observed in rat brain following intravenous infusion at 5 mg/kg/h.

NOVEL COMPOUNDS

The present invention discloses novel compounds inhibiting LRRK2 kinase activity, the preparation processes thereof, the compositions containing them, as well as the use in treating diseases characterized by LRRK2 kinase activity, particularly Parkinson's disease and Alzheimer's disease.